Eligibility to COAPT trial in the daily practice: A real-world experience.
Edoardo ZancanaroNicola BuzzattiPaolo DentiNicolò Azzola GuicciardiEnrico MelilloFabrizio MonacoEustachio AgricolaFrancesco AnconaOttavio AlfieriMichele De BonisFrancesco MaisanoPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2024)
Only a minority (14%) of real-world patients with FMR referred to a tertiary hospital fulfilled the COAPT selection criteria. Among Non-COAPT patients, weighted 4-year survival was higher in patients who received MitraClip compared to those who were left in optimized medical therapy (91.5% [0.864, 0.96] vs. 71.8% [0.509, 0.926], respectively, p = 0.027).
Keyphrases
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- primary care
- magnetic resonance
- clinical trial
- mitral valve
- physical activity
- prognostic factors
- randomized controlled trial
- stem cells
- magnetic resonance imaging
- patient reported outcomes
- atrial fibrillation
- contrast enhanced
- free survival
- bone marrow
- smoking cessation
- open label